Genetic Testing Coronary Artery Disease Microarray Blood

In contrast microarray platforms measure the expression of a large number of genes simultaneously, enabling gene expression profiling across many pathways in parallel. This approach has the potential to represent a comprehensive range of pathophysiological processes of CVD economically and efficiently. Gene expression profiling extends beyond known biomarkers to reveal potential biomarkers which have not previously been reported as associated with CVD. Gene expression analysis can enable us to understand and discover novel and sensitive biomarkers of cardiovascular disease. A number of studies have published work in this area: a gene expression analysis yielded 482 genes with an association to the composition of coronary atherosclerotic plaques and most of them were not previously linked to atherosclerosis. A wide-scale gene expression profiling identified fifty six divergent genes for atherosclerotic and non-atherosclerotic human coronary arteries, wherein 49 were never associated with CAD before. Elashoff and co-authors identified a set of classifying genes which with the information of age and sex were strongly correlated to obstructive CAD in non-diabetic patients. The divergent gene expressions were identified which discriminated ischemic and non-ischemic cardiomyopathies conditions among the end-stage patients. In another study microarray analysis and gene expression profiling were used to discover genes related to heart failure using the expression profiles of 12 patients with heart failure, another study of normal controls and MI patients discovered genetic markers and dysregulated pathways associated with disease recurrence in first time MI patients.